Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-07. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== Cause === As well as attempting to find disease-modifying agents for osteoarthritis, there is emerging evidence that a system-based approach is necessary to find the causes of osteoarthritis. A study conducted by scientists at the University of Twente found that osmolarity induced intracellular molecular crowding might drive the disease pathology.
Most organisms synthesize NAD+ from simple components. The specific set of reactions differs among organisms, but a common feature is the generation of quinolinic acid (QA) from an amino acid – either tryptophan (Trp) in animals and some bacteria, or aspartic acid (Asp) in some bacteria and plants. The quinolinic acid is converted to nicotinic acid mononucleotide (NaMN) by transfer of a phosphoribose moiety. An adenylate moiety is then transferred to form nicotinic acid adenine dinucleotide (NaAD). Finally, the nicotinic acid moiety in NaAD is amidated to a nicotinamide (Nam) moiety, forming nicotinamide adenine dinucleotide. In a further step, some NAD+ is converted into NADP+ by NAD+ kinase, which phosphorylates NAD+. In most organisms, this enzyme uses adenosine triphosphate (ATP) as the source of the phosphate group, although several bacteria such as Mycobacterium tuberculosis and a hyperthermophilic archaeon Pyrococcus horikoshii, use inorganic polyphosphate as an alternative phosphoryl donor.
==== Multiple sclerosis-related fatigue ==== Fatigue is a common and often debilitating symptom experienced by people with multiple sclerosis. Reviews and meta-analyses of controlled trials have found that modafinil has modest effectiveness in managing MS-related fatigue, though improvements in fatigue severity scores have not consistently reached statistical significance. Optimal dosing and treatment schedules are not well established. Clinical assessments have found that adverse events were common. Most MS organizations are neutral on the off-label use of modafinil to alleviate fatigue associated with MS.
Sources: en.wikipedia.org
Dendritic cell vaccines combine dendritic cells with antigens to present the antigens to the body's white blood cells, thus stimulating an immune reaction. These vaccines have shown some positive preliminary results for treating brain tumors and are also tested in melanoma. Recombinant vector – by combining the physiology of one microorganism and the DNA of another, immunity can be created against diseases that have complex infection processes. An example is the RVSV-ZEBOV vaccine licensed to Merck that is being used in 2018 to combat ebola in Congo. T-cell receptor peptide vaccines are under development for several diseases using models of Valley Fever, stomatitis, and atopic dermatitis. These peptides have been shown to modulate cytokine production and improve cell-mediated immunity. Targeting of identified bacterial proteins that are involved in complement inhibition would neutralize the key bacterial virulence mechanism. The use of plasmids has been validated in preclinical studies as a protective vaccine strategy for cancer and infectious diseases. However, in human studies, this approach has failed to provide clinically relevant benefit. The overall efficacy of plasmid DNA immunization depends on increasing the plasmid's immunogenicity while also correcting for factors involved in the specific activation of immune effector cells. Bacterial vector – Similar in principle to viral vector vaccines, but using bacteria instead.
In 2005, Katja Seipel and Volker Schmid suggested that cnidarians and ctenophores are simplified descendants of triploblastic animals, since ctenophores and the medusa stage of some cnidarians have striated muscle, which in bilaterians arises from the mesoderm. They did not commit themselves on whether bilaterians evolved from early cnidarians or from the hypothesized triploblastic ancestors of cnidarians. Resolving the evolutionary relationships within Cnidaria has also been challenging, with almost every possible combination of clades being proposed. As time went on though, a semi-consensus has started to emerge. The enigmatic Polypodium hydriforme and subphylum Myxozoa have been firmly placed within the Cnidaria and have been shown to be closely related to the Medusozoa. In addition, these two groups have been found to likely be each other's closest relatives which, if true, would form the clade "Endocnidozoa". The relationships within the Medusozoa are currently probably the most contentious part of the tree. Traditionally, the class Scyphozoa also included Staurozoa and Cubozoa, but significant morphological differences eventually lead to the split of the three. The group containing them has since been named "Acraspeda". The relationships between these three and Hydrozoa have since and still are debated. A relationship between Scyphozoa and Cubozoa with Staurozoa as its sister has seen support in nearly all studies, but the position of the remaining class, Hydrozoa, is not understood.
=== Singer-songwriter === In 1996, Sheik released his self-titled debut album, which was certified gold. The album featured the hit single "Barely Breathing", which peaked at number 16 and remained on the Billboard Hot 100 for 55 consecutive weeks. "Barely Breathing" also enjoyed Top 20 success on Adult Contemporary radio, reached No. 2 on the Adult Top 40 charts, and garnered Sheik a Grammy Award nomination for Best Male Pop Vocal Performance. In 1998, Sheik recorded "Embraceable You" for Red Hot + Rhapsody, a George Gershwin tribute, and also recorded "Songbird" for another tribute, Legacy: A Tribute to Fleetwood Mac's Rumours. Also in 1998, Sheik released Humming, which featured orchestral and string arrangements. Sheik sang a duet with singer Howard Jones on Jones' 2000 single entitled Someone You Need. He released Phantom Moon, a Nick Drake-influenced album created in collaboration with poet and playwright Steven Sater, in 2001. The following year, Sheik released Daylight, which included the singles "On a High" and "Half-Life". After a four-year recording break, Sheik released White Limousine (2006), which included a DVD allowing listeners to remix and reinterpret songs from the album. In 2009, he released Whisper House, a concept album which provided the score for the musical of the same name. The stage musical premiered at The Old Globe Theatre in San Diego in January 2010, after a workshop at Vassar College, produced by New York Stage and Film in 2009. In 2011, Sheik released Covers 80s, an album including covers of popular 1980s songs.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.